Related Experiment Video

Updated: Jul 18, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

HER2 therapy: molecular mechanisms of trastuzumab resistance

Rita Nahta1, Francisco J Esteva

  • 1Department of Breast Medical Oncology, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030-4009, USA. rnahta@mdanderson.org

Breast Cancer Research : BCR
|November 14, 2006
PubMed

Insights

Trastuzumab is a targeted therapy for HER2-positive breast cancer. This review explores how resistance develops and discusses new treatments to improve patient survival.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Trastuzumab is a monoclonal antibody targeting the HER2 receptor in breast cancer.
  • Therapeutic resistance to trastuzumab develops in most metastatic patients within a year.
  • A significant percentage of patients relapse despite trastuzumab therapy in the adjuvant setting.

Purpose of the Study:

  • To review the antitumor mechanisms of trastuzumab.
  • To elucidate how these mechanisms are altered, leading to therapeutic resistance.
  • To discuss novel therapies that enhance trastuzumab efficacy for HER2-overexpressing breast cancer.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of molecular mechanisms underlying trastuzumab activity and resistance.
  • Exploration of emerging therapeutic strategies and combination treatments.

Main Results:

  • Trastuzumab exhibits antitumor activity through various mechanisms, including antibody-dependent cell-mediated cytotoxicity and direct inhibition of HER2 signaling.
  • Acquired resistance involves alterations in HER2 pathway signaling, activation of bypass pathways, and changes in the tumor microenvironment.
  • Emerging therapies aim to overcome resistance by targeting alternative pathways, enhancing immune responses, or utilizing novel antibody formats.

Conclusions:

  • Understanding trastuzumab resistance mechanisms is crucial for developing effective treatment strategies.
  • Novel therapeutic approaches hold promise for improving outcomes in patients with HER2-overexpressing breast cancer.
  • Combination therapies and personalized treatment strategies are key to overcoming resistance and improving survival.

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...